Anna Aleksandrovna Zuikova

Anna Aleksandrovna Zuikova

Auto-generated profile, based on publicly available information

Anna Aleksandrovna Zuikova

NN Burdenko Voronezh State Medical University, Voronezh, Russia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2023 in Folia Medica
Verified
Journal Article
Open access
PDF file
ISIrina Starodubtseva
Irina Starodubtseva
MMMaria Meshkova
Maria Meshkova
AZAnna Zuikova
Anna Zuikova
Stent restenosis is the most unfavorable complication of interventional treatment for coronary heart disease. We already know from various literature sources that the causes for stent restenosis in patients are both mechanical damage (partial opening, stent breakage, extended stented area, calcification, incomplete stent coverage of atherosclerotic plaque, weak radial stiffness of the stent metal frame, lack of stent drug coating), and the neointimal hyperplasia formation which is closely related to the de novo atherosclerosis development, being a predictor of the recurrent cardiovascular event. Considering this event, it is necessary to understand all the pathogenetic and pathophysiological processes of atherosclerosis. This review aims to comprehensively highlight the main issues of pathogenesis and the development of stent restenosis in the coronary artery after percutaneous transluminal coronary angioplasty. The review is based on relevant publications found by a selective search of PubMed, Google Scholar, Scopus, Web of Science, and eLibrary, including works published within the last 20 years. The influence of various factors of the pathogenetic process on the risk of stent restenosis has been demonstrated.

24 January 2023 in Journal of Clinical Practice
Verified
Journal Article
Open access
AZAnna Aleksandrovna Zuikova
Anna Aleksandrovna Zuikova
VSVeronika I. Shevcova
Veronika I. Shevcova
ASArtem N. Shevcov
Artem N. Shevcov
AKAnastasia Sergeevna Kurguzova
Anastasia Sergeevna Kurguzova
Sarcopenia is a multifactorial syndrome with an insufficiently studied pathogenesis, manifested by a generalized loss of muscle mass and skeletal muscle strength. Despite the fact that sarcopenia is a risk factor for mortality and disability, especially in the elderly, this pathology is rarely diagnosed. The lack of the uniform criteria for the diagnosis and comorbidity of the elderly patients create difficulties in the differential diagnosis of this condition. Sarcopenia is most often combined with endocrine pathologies, such as obesity and diabetes mellitus. An accelerated decrease in the muscle mass leads to a decrease in insulin sensitivity, resulting in insulin resistance, which, in turn, leads to the excessive accumulation of adipose tissue sarcopenic obesity. The results of the studies indicate a higher risk of metabolic syndrome, type 2 diabetes mellitus and atherosclerosis among individuals with sarcopenic obesity, as opposed to those with simple obesity or sarcopenia. A vicious circle consisting of age-related changes in the skeletal muscles, obesity and impaired glucose regulation leads to a more severe course of diseases and a negative impact on a person's life expectancy. Due to the fact that there are presently no clear criteria for the diagnosis of sarcopenic obesity, there are no unambiguous data on its prevalence. A search for the modern methods of research, prevention and treatment of this condition is required.

24 November 2022 in Лечащий врач
Verified
Journal Article
Closed access
AZA.A. Zuikova
A.A. Zuikova
DBD.YU. Bugrimov
D.YU. Bugrimov
OKO.N. Krasnorutskaya
O.N. Krasnorutskaya
Along with the obvious clinical symptoms caused by the reactivity of the cytokine storm syndrome, patients experience extrapulmonary manifestations of COVID-19. A thorough analysis of large arrays of patients showed that residual symptoms in people with microbiological normalization (i. e., with negative results of the SARS-CoV-2 virus as a criterion for the effectiveness of etiotropic treatment) represent a complex of clinical manifestations that have a single etiopathogenesis, and thus the following is formed concept as post-covid syndrome. Post-covid syndrome has become one of the leading consequences of a new coronavirus infection. The physical, cognitive and neuropsychological consequences of the disease are increasingly becoming realistic, and the associated functional limitations may persist long after discharge from the hospital, negatively affecting the quality of life of patients. Modern ideas of a number of foreign scientists about the manifestations and pathogenesis of post-covid syndrome are reduced to the following aspects: symptoms caused by persistent chronic inflammation are combined with the consequences of damage to internal organs and non-specific manifestations of hospitalization and social isolation. One of the evidence of the pathogenesis of post-covid syndrome is the change in biomarkers, which are criteria for impaired cognitive-motor and psycho-cognitive states of coronavirus infection. The article analyzes the practical experience of using programs for the rehabilitation treatment of patients with COVID-19 in outpatient medical organizations, taking into account changes and prediction of further development of post-COVID syndrome based on the dynamics of concentrations of patients' blood biomarkers. Comprehensive rehabilitation treatment of patients with COVID-19, based on the individual selection of not only physical and physiotherapeutic treatment regimens, but also on the use of drugs, especially drugs that stimulate regeneration and repair, will help to avoid many of the negative consequences of the pathology.

26 May 2021 in Cardiosomatics
Verified
Journal Article
Open access
PDF file
YKYuliya A. Kotova
Yuliya A. Kotova
AZAnna A. Zuikova
Anna A. Zuikova
NSNatalia V. Strahova
Natalia V. Strahova
OKOlga N. Krasnorutskaya
Olga N. Krasnorutskaya
EEElena Y. Esina
Elena Y. Esina
Aim. To study the role of markers of endothelial dysfunction, oxidative and cellular stress in the prediction of myocardial infarction (MI) in comorbid patients with stable coronary heart disease (CHD). Material and methods. The study involved 336 patients with a diagnosis of CHD. The presence of CHD was confirmed by diagnostic coronary angiography with the calculation of the Gensini index. All patients were divided into 2 groups: group 1288 patients without a history of MI, group 248 patients with a history of MI. All patients were assessed for the levels of oxidized modified proteins, high-sensitivity C-reactive protein (hs-CRP), homocysteine, heat shock protein (HSP70), and superoxide dismutase activity. Results. All patients were comparable in age. For other clinical and anthropometric characteristics, we saw significant differences (according to the MannWhitney criterion): patients with previous MI had higher BMI, waist circumference, and blood pressure. The correlation analysis revealed positive significant average strength relationships between past MI and the Gensini index, low-density lipoprotein level, total cholesterol level, homocysteine level, hs-CRP level, and the level of oxidized modified proteins; and negative significant average strength relationships between past MI and SOD activity level (r=-0.374, p=6.4 E-07) and HSP70 level (r=-0.563, p=2.6 E-15). The ROC analysis revealed that not all markers were significant in predicting the risk of MI. It is shown that the most expected characteristics were shown by the hs-СRP. However, further analysis of the predictive significance of the markers demonstrated that the addition of HSP70 to hs-CRP increases the predictive significance of hs-CRP in relation to the risk of developing MI. Conclusion. We have demonstrated that a strategy using a cumulative risk assessment consisting of 2 biomarkers (individually involved in inflammation and stress-induced cellular responses) can identify patients with an established diagnosis of CHD who have an increased risk of acute MI.

30 June 2020 in "Medical & Pharmaceutical Journal "Pulse"
Verified
Journal Article
Closed access
YKYu.A. Kotova
Yu.A. Kotova
AZA.A. Zuikova
A.A. Zuikova
NSN.V. Strakhova
N.V. Strakhova
OKO.N. Krasnorutskaya
O.N. Krasnorutskaya

1 January 2022 in Bulletin of Medical Science
Verified
Journal Article
Closed access
EYE.Yu. Yesina
E.Yu. Yesina
YKYu.A. Kotova
Yu.A. Kotova
AZA.A. Zuikova
A.A. Zuikova